medi-cal glp 1 coverage BREAKING: Ends for Ozempic, Wegovy, Mounjaro & All GLP-1 Weight-Loss Drugs Jan 1, 2026, Sacramento, CA (Nov 2, 2025), California’s Medi-Cal will stop covering GLP-1 drugs (Ozempic, California Medi-Cal halts GLP-1 obesity

It is not a licensed medicinal product and is not approved for human consumption or clinical administration

While it may seem economical, needle reuse significantly increases the risk of infection, causes needles to become dull and bent, and can lead to painful injections and tissue damage

While microbial colonization does not influence the quantity of B cells at different developmental stages in the bone marrow and spleen, it may facilitate B cell maturation in peripheral immune organs, augment the proportion of mature B cells, and enhance the diversity of the B cell receptor (BCR) repertoire

Let me rephrase this

Wang J, Gao Y, Xiao L, Lin Y, Huang L, Chen J, et al

We further identify the aa72-86 loop domain of SLC25A39 as essential for its recruitment to AFG3L2 and subsequent degradation